RB1 and neoplasm: In an ICC cohort of 169 cases with >10 years of follow-up, we found that stromal PRB independently conferred a lower risk (hazard ratio 0.39, 95% CI: 0.18–0.87, p = 0.022) of 5-year mortality considering age, histology, FIGO stage, tumor differentiation, and lymphatic and hematogenous metastasis.